Tolerance to Pituitary-Adrenal Axis Activation by Anticancer Drugs in Normal and Tumour-Bearing Rats
Cisplatinum given intravenously (i.V.), hydroxyurea given orally (os), procarbazine (os) and L-asparaginase (i.V.), on a decreasing scale, produce significant (p< 0.01) adrenocortical activation over 4-h period at a single dose per kg 10 times higher than those employed in human therapy. Only hydroxyurea retained this activity after a 5-day treatment both in normal and Walker carcinosarcoma-bearing rats. Adrenocortical activation depends on the presence of pituitary ACTH both after single or repeated treatments.
Key wordsL-Asparaginase Cisplatinum Hydroxyurea Procarbazine ACTH Hypothalamus-hypophyseal-adrenal axis Adrenal cortex -Cancer chemotherapy Drug effects Tolerance Walter carcinosarcoma
Unable to display preview. Download preview PDF.
- Calabresi P, Parks RE Jr (1980) Chemotherapy of neoplastic disease. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Saunders, New York, pl 301Google Scholar
- Craddock CG (1978) Corticosteroid-induced lymphopenia, immunosuppression and body defense. Ann Intern Med 28: 564–566Google Scholar
- Salmon SE (1980) Cancer chemotherapy. In: Meyers FH, Jawetz E, Goldfien A (eds) Medical pharmacology. Lange Med Publ, Los Altos, California, pp 477–513Google Scholar
- Vacca M, Cerrito F, Balzamo S, Preziosi P (1982) Pituitary adrenal axis and plasma prolactin following administration of clinically-useful anticancer drugs. Presented at the XXI Ital Cong of Pharmacology, June 2–5, 1982, Naples, Italy. Abs Book, p 191 (abstr. 51)Google Scholar